COMP <GO>
PRAX vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Praxis Precision Medicines Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PRAX 3
— LLY 11
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: LLY
LAST: $285.93 (-0.93%) • MKT CAP: $8.06B
dividend-safety
0.00%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRAX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRAX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 83.64% | -39.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.09% | 2.30% | -5.39 | LLY | /fcf-yield <GO> |
| Operating Margin | 16.50% | 40.21% | -23.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 31.90% | -19.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 45.51% | -36.71 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | PRAX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.77% | -0.17 | PRAX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.0 | 77.9 | -22.86 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.51 | +0.40 | PRAX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 26.3x | +6.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.06B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRAX REV | LLY REV | PRAX GROSS % | LLY GROSS % | PRAX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$249.1M | $16.81B |
| FY 2024 | $8.6M | $45.04B | 44.0% | 81.3% | -$131.8M | $8.82B |
| FY 2023 | $2.4M | $34.12B | 44.0% | 79.3% | -$111.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRAX // BETA 0.91
LLY // BETA 0.51